Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0324)
Drug Name
Cilostazol
Synonyms
Cilostazole; Cilostazolum; Cilostazolum [INN-Latin]; OPC 13013; OPC 21; OPC-13013; OPC-21; Pletaal; Pletal; cilostazol; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 73963-72-1; BRN 3632107; C20H27N5O2; CHEBI:31401; MLS000028470; UNII-N7Z035406B
Indication Arteriosclerosis obliterans [ICD11: BD40] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 369.5 Topological Polar Surface Area 81.9
Heavy Atom Count 27 Rotatable Bond Count 7
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
2754
PubChem SID
855683 ; 6897916 ; 7848958 ; 7978527 ; 8151779 ; 11110906 ; 11113335 ; 11372358 ; 11374323 ; 11484992 ; 11488934 ; 11490985 ; 11492587 ; 11528739 ; 12012700 ; 14755273 ; 14828756 ; 17404781 ; 24278291 ; 26612838 ; 26680450 ; 26719653 ; 26719654 ; 26746958 ; 26746959 ; 29221909 ; 46386747 ; 46386994 ; 46506317 ; 47365365 ; 48259412 ; 48259413 ; 49834949 ; 50100194 ; 50103999 ; 50104000 ; 50409718 ; 53777324 ; 53787948 ; 56422089 ; 56463107 ; 57321435 ; 68530811 ; 85230957 ; 85787626 ; 87218800 ; 87218801 ; 87219014 ; 90341176 ; 92124839
ChEBI ID
CHEBI:31401
CAS Number
73963-72-1
TTD Drug ID
D03VPC
Formula
C20H27N5O2
Canonical SMILES
C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
InChI
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChIKey
RRGUKTPIGVIEKM-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
OPC-13213 DM001846
10022985
Unclear 1 [3] , [4]
OPC-13326 DM001843
10045635
Unclear 1 [3] , [4]
OPC-13015 DM001844
10021885
Unclear 2 [3] , [5]
OPC-13213 DM001846
10022985
Unclear 2 [3] , [5]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000657 Cilostazol OPC-13326 Unclear CYP3A4 [3], [4]
MR000658 Cilostazol OPC-13213 Unclear CYP3A5 ... [3], [4]
MR000656 OPC-13213 OPC-13213 Unclear Unclear [3], [5]
MR000655 OPC-13326 OPC-13015 Unclear Unclear [3], [5]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A7 (CYP3A7) DME0015 Homo sapiens
CP3A7_HUMAN
1.14.14.1
[2]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[2]
⏷ Show the Full List of 6  DME(s)
References
1 Cilostazol was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
3 Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography J Pharm Biomed Anal. 2001 Jan;24(3):381-9. doi: 10.1016/s0731-7085(00)00426-x.
4 Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol Drug Metab Dispos. 2007 Oct;35(10):1730-2. doi: 10.1124/dmd.107.016758.
5 Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites Eur J Clin Pharmacol. 2018 Nov;74(11):1417-1426. doi: 10.1007/s00228-018-2522-5.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.